Notes in NSCLC

To Subscribe, use this Key

Status	Last Update	Fields
Published	02/18/2024	Lu&M \| NSCLC \| 1.1 \| Epidemiology
Published	02/18/2024	Lu&M \| NSCLC \| 1.2.1 \| Risk factors \| List the risk factors for NSCLC
Published	02/18/2024	Lu&M \| NSCLC \| 1.2.2 \| Aetiology and risk factors \| Describe the aetiology and risk factors for NSCLC
Published	02/18/2024	Lu&M \| NSCLC \| 1.3.1.1 \| Pathologic classification \| List the types of lung tumours as per the WHO 2015 classification
Published	02/18/2024	Lu&M \| NSCLC \| 1.3.0 \| Normal histology - describe the normal epithelium of the respiratory tract
Published	02/18/2024	Lu&M \| NSCLC \| 1.3.2.1 \| Immunohistochemistry \| Discuss issues and recommendations regarding making the diagnosis of NSCLC from a small biopsy and…
Published	02/18/2024	Lu&M \| NSCLC \| 1.3.2.2 \| Immunohistochemistry \| Describe the IHC stains you would use to distinguish:- Poorly differentiated lung adenocarcinoma f…
Published	02/18/2024	Lu&M \| NSCLC \| 1.3.1.2 \| Pathologic subtypes \| Comparison of path subtypes \| Compare the definition, location and biological behaviour, epidemiolo…
Published	02/18/2024	Lu&M \| NSCLC \| 1.3.1.2.2 \| Pathologic subtypes \| Adenocarcinoma \| Micro \| Decsribe the microscopic features of the subtypes of lung adenocari…
Published	02/18/2024	Lu&M \| NSCLC \| 1.3.1.2.3 \| Pathologic subtypes \| Adenocarcionma \| Molecular features \| Discuss the molecular features of lung adenocarcinomas
Published	02/18/2024	Lu&M \| NSCLC \| 1.3.1.3.1 \| Pathologic subtypes \|  SCC \| Epidemiology, RFs,  BB, Macroscopic, Microscopic description, IHC
Published	02/18/2024	Lu&M \| NSCLC \| 1.3.1.4 \| Pathologic subtypes \| Adenosquamous carcinoma \| Describe the microscopic features of and clinical implications of ad…
Published	02/18/2024	Lu&M \| NSCLC \| 1.3.1.5 \| Pathologic subtypes \| Large cell carcinoma \| Describe the definition, clinical and microscopic features of large cell car…
Published	02/18/2024	Lu&M \| NSCLC \| 1.3.1.6 \| Pathologic subtypes \| Sarcomatoid carcinoma \| Discuss the definition, incidence, clinical implications, subtypes and mirc…
Published	02/18/2024	Lu&M \| NSCLC \| 1.4 \| Patterns of spread and biological behaviour
Published	02/18/2024	Lu&M \| NSCLC \| 1.3.3.1 \| Molecular pathology \| Driver mutations \| List the common driver mutations in NSCLC
Published	02/18/2024	Lu&M \| NSCLC \| 1.3.3.1.1 \| Molecular pathology \| Driver mutations \| EGFR mutation \| Describe the specific mutations, pathophysiology, epidemiology…
Published	02/18/2024	Lu&M \| NSCLC \| 1.3.3.1.2 \| Molecular pathology \| Driver mutations \| ALK rerrangement \| Describe the pathophysiology, epidemiology, testing methods…
Published	02/18/2024	Lu&M \| NSCLC \| 1.3.3.1.3 \| Molecular pathology \| Driver mutations \| ROS1 gene rearrangement \| Describe the pathophysioloygy, epidemiology, clinica…
Published	02/18/2024	Lu&M \| NSCLC \| 1.3.3.1.4 \| Molecular pathology \| Driver mutations \| BRAF V600E point mutation \| Describe the epidemiology, clinical implications a…
Published	02/18/2024	Lu&M \| NSCLC \| 1.3.3.2 \| Molecular pathology \| PD-L1/TPS scoring
Published	02/18/2024	Lu&M \| NSCLC \| 1.3.3.3 \| Molecular pathology \| Emerging predictive biomarkers \| List some emerging predictive biomarkers (other than driver mutati…
Published	02/18/2024	Lu&M \| NSCLC \| 1.5 \| Screening \| Discuss the role of screening in NSCLC
Published	02/18/2024	Lu&M \| NSCLC \| 1.6 \| Clinical presentation \| List the potential presenting features of NSCLC and where relevant link briefly to pathology
Published	02/18/2024	Lu&M \| NSCLC \| 1.7.1 \| Imaging appearance \| Describe the imaging appearance of NSCLC
Published	02/18/2024	Lu&M \| NSCLC \| 1.7.2 \| Imaging appearance \| List differential diagnoses for NSCLC on imaging
Published	02/18/2024	Lu&M \| NSCLC \| 2.1.1 \| Workup \| Approach \| List your approach to workup of a patient with suspected lung cancer
Published	02/18/2024	Lu&M \| NSCLC \| 2.1.2 \| Workup \| Tissue diagnosis \| Describe the advantages and disadvantages of the various options for obtaining a tissue diagnos…
Published	02/18/2024	Lu&M \| NSCLC \| 2.1.2 \| Workup \| PFTs \| Describe the features on pulmonary function tests relevant for fitness for definitive treatment of NSCLC wi…
Published	02/18/2024	Lu&M \| NSCLC \| 2.1.3 \| Workup \| PET \| Discuss the role of PET in the management of NSCLC
Published	02/18/2024	Lu&M \| NSCLC \| 2.1.4 \| Workup \| Solitary pulmonary nodule \| Describe your approach to evaluation of a solitary pulmonary nodule
Published	02/18/2024	Lu&M \| NSCLC \| 2.1.5.1 \| Staging \| AJCC 8th edition \| Describe the AJCC 8th edition staging system for NSCLC
Published	02/18/2024	Lu&M \| NSCLC \| 2.1.5.2 \| Staging \| AJCC 8th edition vs. 7th edition \| Outline the differences between the new 8th edition and the old 7th edition …
Published	02/18/2024	Lu&M \| NSCLC \| 2.1.6 \| Prognostic factors \| List the prognostic factors for NSCLC
Published	02/18/2024	Lu&M \| NSCLC \| 3.1.1 \| Management \| Overview \| Create a table to summarise the stage-by-stage (clinical staging) management of NSCLC for a fit pat…
Published	02/18/2024	Lu&M \| NSCLC \| 3.1.5 \| Management \| Overview \| Recurrence \| Briefly describe the management of recurrent NSCLC
Published	02/18/2024	Lu&M \| NSCLC \| 3.1.2 \| Management \| Overview \| Stage I-II \| Provide your overview of the management paradigm for stage I-II NSCLC
Published	02/18/2024	Lu&M \| NSCLC \| 3.1.3 \| Management \| Overview \| Stage III \| Provide your overview of the management paradigm for stage III NSCLC
Published	02/18/2024	Lu&M \| NSCLC \| 3.1.4 \| Management \| Overview \| Stage IV \| Provide your overview of the management paradigm for stage IV NSCLC
Published	02/18/2024	Lu&M \| NSCLC \| 3.2.1.1 \| Management \| Operable \| Principles of surgery \| Patient selection for surgery \| Discuss the selection of patients for sur…
Published	02/18/2024	Lu&M \| NSCLC \| 3.2.1.2 \| Management \| Operable \| Principles of surgery \| Surgical techniques \| Discuss various surgical techniques which may be em…
Published	02/18/2024	Lu&M \| NSCLC \| 3.2.2.2 \| Management \| Operable \| Neoadjuvant chemotherapy \| Discuss the role of neoadjuvant chemotherapy prior to surgery for oper…
Published	02/18/2024	Lu&M \| NSCLC \| 1.3.1.2 \| Pathologic classification \| Discuss the differences between the current WHO 2015 classificaiton system and the WHO 2004 c…
Published	02/18/2024	Lu&M \| NSCLC \| 3.2.2.1 \| Management \| Operable \| Adjuvant chemotherapy \| Discuss the role of adjuvant chemotherapy following surgery in operable N…
Published	02/18/2024	Lu&M \| NSCLC \| 3.2.3.1 \| Management \| Operable \| Adjuvant radiotherapy (PORT) \| List the indications for adjuvant radiotherapy following surgery f…
Published	02/18/2024	Lu&M \| NSCLC \| 3.2.3.2 \| Management \| Operable \| Adjuvant radiotherapy (PORT) \| Discuss the evidence for adjuvant radiotherapy following surgery f…
Published	02/18/2024	Lu&M \| NSCLC \| 4.2 \| RT Planning \| Operable \|  Adjuvant RT pN2 \| OUTDATED Describe your technique for adjuvant radiotherapy following surgery…
Published	02/18/2024	Lu&M \| NSCLC \| 4.3 \| RT Planning \| Operable \|  Adjuvant RT R1/2 \| Describe your technique for adjuvant radiotherapy following surgery for ope…
Published	02/18/2024	Lu&M \| NSCLC \| 3.2.3.3 \| Management \| Operable \| Adjuvant radiotherapy (PORT) \| R1/R2 disease \| Discuss the evidence for adjuvant radiotherapy in …
Published	02/18/2024	Lu&M \| NSCLC \| 3.2.3.4 \| Management \| Operable \| Intraoperative brachytherapy \| Discuss the role of intraoperative brachytherapy in the management…
Published	02/18/2024	Lu&M \| NSCLC \| 3.2.4 \| Management \| Operable \| Locoregional recurrence following surgery \| Briefly describe the management of locoregional-only re…
Published	02/18/2024	Lu&M \| NSCLC \| 3.3.1 \| Management \| Stage I-II Inoperable \| Prognosis \| Discuss the prognosis of early-stage inoperable NSCLC
Published	02/18/2024	Lu&M \| NSCLC \| 3.3.2 \| Management \| Stage I-II Inoperable \| SBRT \| List the features of SBRT in the context of early NSCLC
Published	02/18/2024	Lu&M \| NSCLC \| 3.3.4 \| Management \| Stage I-II Inoperable \| SBRT \| SBRT vs. Conventional fractionation \| Discuss the evidence comparing SBRT to co…
Published	02/18/2024	Lu&M \| NSCLC \| 3.3.3 \| Management \| Stage I-II Inoperable \| SBRT \| Early non-randomised evidence from prospective phase II studies \| Briefly discu…
Published	02/18/2024	Lu&M \| NSCLC \| 3.3.5 \| Management \| Stage I-II (operable) \| SBRT \| SBRT vs. Surgery \| Discuss the randomised evidence comparing SBRT and surgery f…
Published	02/18/2024	Lu&M \| NSCLC \| 3.3.6.1.1 \| Management \| Stage I-II inoperable \| SBRT \| Central tumours \| Definition \| Discuss the definition of central tumours
Published	02/18/2024	Lu&M \| NSCLC \| 3.3.6.1.2 \| Management \| Stage I-II inoperable \| SBRT \| Central tumours \| Safety \| Discuss the safety concerns regarding treamtent …
Published	02/18/2024	Lu&M \| NSCLC \| 3.3.6.2.1 \| Management \| Stage I-II inoperable \| SBRT \| Ultra-central tumours \| Definition \| Discuss the definition of ultra-centra…
Published	02/18/2024	Lu&M \| NSCLC \| 3.3.6.2.2 \| Management \| Stage I-II inoperable \| SBRT \| Ultra-central tumours \| Safety \| Discuss the safety concerns regarding SBRT…
Published	02/18/2024	Lu&M \| NSCLC \| 3.3.9 \| Management \| Stage I-II inoperable \| RFA \| Discuss the role of radiofrequency ablation in the management of early-stage ino…
Published	02/18/2024	Lu&M \| NSCLC \| 3.3.8 \| Management \| Stage I-II inoperable \| Conventionally fractionated RT \| Discuss the role of conventionally fractionated radio…
Published	02/18/2024	Lu&M \| NSCLC \| 3.4.1.1 \| Management \| Stage IIIA \|  Describe your approach to the management of stage IIIA NSCLC
Published	02/18/2024	Lu&M \| NSCLC \| 3.4.1.2 \| Management \| Stage IIIA \| Evidence overview \| Provide an overview of the management of stage IIIA NSCLC (briefly mentioni…
Published	02/18/2024	Lu&M \| NSCLC \| 3.4.1.3 \| Management \| Stage IIIA \| Surgery alone vs.  induction RT -> surgery \| Is there a role for induction RT alone pri…
Published	02/18/2024	Lu&M \| NSCLC \| 3.4.1.4 \| Management \| Stage IIIA \| Induction chemoradiotherapy + surgery vs. definitive chemoradiotherapy \| Discuss the evidence c…
Published	02/18/2024	Lu&M \| NSCLC \| 3.4.1.5 \| Management \| Stage IIIA \| Induction chemo -> Surgery vs. Surgery alone \| Discuss the role of neoadjuvant chemotherapy …
Published	02/18/2024	Lu&M \| NSCLC \| 3.4.1.6 \| Management \| Stage IIIA \| Induction chemo vs. induction chemoRT prior to surgery \| Discuss the evidence that compares ind…
Published	02/18/2024	Lu&M \| NSCLC \| 3.4.1.7 \| Management \| Stage IIIA \| Induction chemo -> surgery vs. induction chemo -> RT \| Discuss the evidence comparing the…
Published	02/18/2024	Lu&M \| NSCLC \| 3.4.2.1 \| Management \| Stage III inoperable \| Overview \| Describe your approach to management of unresectable stage III NSCLC
Published	02/18/2024	Lu&M \| NSCLC \| 3.4.2.2 \| Management \| Stage III inoperable \| Sequential chemotherapy -> radiotherapy \| Discuss the role of sequential chemother…
Published	02/18/2024	Lu&M \| NSCLC \| 3.4.2.3.1 \| Management \| Stage III inoperable \| Concurrent chemoradiotherapy \| Discuss the role of concurrent chemoradiotherapy in …
Published	02/18/2024	Lu&M \| NSCLC \| 3.4.2.3.2 \| Management \| Stage III inoperable \| Concurrent chemoradiotherapy \| Choice of chemotherapy agent \| Discuss the choice of…
Published	02/18/2024	Lu&M \| NSCLC \| 3.4.2.3.3 \| Management \| Stage III inoperable \| Concurrent chemoradiotherapy \| Consolidation chemotherapy \| Discuss the r…
Published	02/18/2024	Lu&M \| NSCLC \| 3.4.2.4 \| Management \| Stage III inoperable \| Adjuvant immunotherapy \| Discuss the role of adjuvant immunotherapy following concurr…
Published	02/18/2024	Lu&M \| NSCLC \| 3.4.2.5 \| Management \| Stage III inoperable \| Definitive RT alone \| Discuss the role of definitive radiotherapy alone for inoperabl…
Published	02/18/2024	Lu&M \| NSCLC \| 3.4.2.6 \| Management \| Stage III inoperable \| Definitive RT alone \| Altered fractionation \| Discuss the role of altered fractionati…
Published	02/18/2024	Lu&M \| NSCLC \| 3.5 \| Management \| Palliative radiotherapy \| Discuss the role of palliative radiotherapy in patients with NSCLC not suitable for cu…
Published	02/18/2024	Lu&M \| NSCLC \| 3.6 \| Management \| Palliative concurrent chemoradiotherapy \| Discuss the role of palliative concurrent chemoradiotherapy in the man…
Published	02/18/2024	Lu&M \| NSCLC \| 3.6.1 \| Management \| Oligometastatic disease \| Overview \| Discuss the management of patients with oligometastatic NSCLC
Published	02/18/2024	Lu&M \| NSCLC \| 3.6.3 \| Management \| Oligometastatic disease \| Brain metastases \| Discuss metastasis-directed management of oligometastases to the …
Published	02/18/2024	Lu&M \| NSCLC \| 3.6.2 \| Management \| Oligometastatic disease \| Management of the primary / nodes \| Discuss the management of the primary in patient…
Published	02/18/2024	Lu&M \| NSCLC \| 3.7.1 \| Management \| Stage IVB \| Overview \| Provide an overview of the management of patients with stage IVB NSCLC
Published	02/18/2024	Lu&M \| NSCLC \| 3.7.2 \| Management \| Stage IVB \| Prognosis \| Create a table to describe the efficacy of treatment and prognosis of patients with ad…
Published	02/18/2024	Lu&M \| NSCLC \| 3.7.2 \| Management \| Stage IVB \| Driver mutation present \| Discuss the evidence for the use of tyrosine kinase inhibitors for patie…
Published	02/18/2024	Lu&M \| NSCLC \| 3.7.2 \| Management \| Stage IVB \| Cytotoxic chemotherapy (vs. observation) \| Discuss the evidence supporting the use of cytotoxic ch…
Published	02/18/2024	Lu&M \| NSCLC \| 3.7.2 \| Management \| Stage IVB \| Immunotherapy and bevacizumab \| Discuss the role of first line immunotherapy and bevacizumab in th…
Published	02/18/2024	Lu&M \| NSCLC \| 3.5.1\| Management \| Endobronchial brachytherapy \| Discuss the role of endobronchial brachytherapy
Published	02/18/2024	Lu&M \| NSCLC \| 3.4.3.1 \| Pancoast (superior sulcus) tumour \| Key features \| Discuss the key features of a pancoast tumour
Published	02/18/2024	Lu&M \| NSCLC \| 3.4.3.2 \| Pancoast (superior sulcus) tumour \| Clinical presentation \| Discuss the clinical presentation of a pancoast tumour
Published	02/18/2024	Lu&M \| NSCLC \| 3.4.3.3 \| Pancoast (superior sulcus) tumour \| Differential diagnosis \| List differential diagnoses for a pancoast tumour
Published	02/18/2024	Lu&M \| NSCLC \| 3.4.3.4 \| Pancoast (superior sulcus) tumour \| Workup \| List your workup for a pancoast tumour
Published	02/18/2024	Lu&M \| NSCLC \| 3.4.3.5 \| Pancoast (superior sulcus) tumour \| Prognostic factors \| List prognostic factors for a pancoast tumour
Published	02/18/2024	Lu&M \| NSCLC \| 3.4.3.5 \| Pancoast (superior sulcus) tumour \| Management \| List the management options for a pancoast tumour
Published	02/18/2024	Lu&M \| NSCLC \| 3.4.3.6 \| Pancoast (superior sulcus) tumour \| Neoadjuvant chemoRT + Surgery \| Discuss the role and protocol for neoadjuvant chemora…
Published	02/18/2024	Lu&M \| NSCLC \| 3.4.3.7 \| Pancoast (superior sulcus) tumour \| Definitive chemoradiotherapy \| Discuss the role of definitive chemoradiotherapy for p…
Published	02/18/2024	Lu&M \| NSCLC \| 3.4.3.7 \| Pancoast (superior sulcus) tumour \| Palliative radiotherapy \| Discuss the role of palliative radiotherapy for pancoast tu…
Published	02/18/2024	Lu&M \| NSCLC \| 4.4 \| RT Planning \| Stage III inoperable \| Concurrent chemoradiotherapy \| RT Planning Descibe your technique for definitive radioth…
Published	02/18/2024	Lu&M \| NSCLC \| 4.5 \| RT Planning \| Pancoast \| Neoadjuvant chemoradiotherapy \| Describe your technique for neoadjuvant chemoradiotherapy for a panc…
Published	02/18/2024	Lu&M \| NSCLC \| 1.3.1.2.1 \| Pathologic subtypes \| Adenocarcinoma \| Epidemiology, aetiology, BB, macroscopic and microscopic appearance, IHC, m…
Published	02/18/2024	Lu&M \| NSCLC \| 1.3.3.1.4 \| Molecular pathology \| Driver mutations \| MET
Status	Last Update	Fields